Sanai Health Group (01889) announced that on April 17, 2024, the company is a wholly-owned subsidiary of Sanai International Investment...
Zhitong Finance App News, Sanai Health Group (01889) announced that on April 17, 2024, the company's wholly-owned subsidiary Sanai International Investment Co., Ltd. plans to sell 59% of the entire issued share capital of Zentrogene Bioscience Laboratory Limited to Merit Investment Holding Limited at a cost of HK$22 million, to be settled in cash.
According to reports, the target company is an indirect wholly-owned subsidiary of the company, which is mainly engaged in providing (including) genetic testing and molecular biological diagnosis services. The target company operates a laboratory with the required license in Hong Kong to provide services such as non-invasive prenatal diagnosis, cancer genetic screening, DNA testing and paternity testing.
After reviewing the target company's performance and strategic positioning, the board of directors believes that the partial divestment will enable management to reallocate energy and resources to the core pharmaceutical business. The divestment will also provide the Group with additional working capital.